Center for Structural Biology

CSB in a nutshell

Science directors: Jan Steyaert & Han Remaut

Structural biology is undergoing a major leap forward in defining three-dimensional submicroscopic structures thanks to cryo-electron microscopy (cryo-EM) and novel approaches to imaging in cell biology. CSB is an integrated center that supports the major methodologies for structural biology (biophysics, NMR, X-ray and cryoEM) complemented with unique and differentiating platforms (Nanobody technology). This interdisciplinary and integrative approach gives us enormous leverage to produce excellent educational opportunities, carry out grand challenge science, and stimulate research-based economic development.

News

Labs

Name
Jan Steyaert
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Anastassia Vorobieva
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Charles Van der Henst
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Han Remaut
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Janine Brunner
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Joris Messens
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Peter Tompa
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Remy Loris
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Rouslan Efremov
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Shoshana Wodak
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology - visiting scientist

Impact on society

Nanobodies, our legacy

Nanobodies, our legacy

In 1989, Professor Raymond Hamers' laboratory at VUB discovered a new type of antibody in the blood of a dromedary. This led to the development of single-domain antibodies known as VHHs or Nanobodies® by former VIB researcher Serge Muyldermans. These tiny antibody fragments have resulted in the establishment of five VIB spin-off companies, including Ablynx, Biotalys, Confo Therapeutics, ExeVir Bio, and Animab. These companies are exploring the potential of VHHs as therapeutics for human and livestock diseases, crop protection, and drug discovery. Ongoing research at VIB continues to contribute to technological innovations in the VHH field.

Start ups